The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events: An Individual Participant Data Analysis From 6 Prospective Cohorts
Open accessAbstract
Background—: American College of Cardiology/American Heart Association guidelines for the diagnosis and management of heart failure recommend investigating exacerbating conditions such as thyroid dysfunction, but without specifying the impact of different thyroid-stimulation hormone (TSH) levels. Limited prospective data exist on the association between subclinical thyroid dysfunction and heart failure events. Methods and Results—: We performed a pooled analysis of individual participant data using all available prospective cohorts with thyroid function tests and subsequent follow-up of heart failure events. Individual data on 25 390 participants with 216 248 person-years of follow-up were supplied from 6 prospective cohorts in the United States and Europe. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L, subclinical hypothyroidism as TSH of 4.5 to 19.9 mIU/L, and subclinical hyperthyroidism as TSH <0.45 mIU/L, the last two with normal free thyroxine levels. Among 25 390 participants, 2068 (8.1%) had subclinical hypothyroidism and 648 (2.6%) had subclinical hyperthyroidism. In age- and sex-adjusted analyses, risks of heart failure events were increased with both higher and lower TSH levels ( P for quadratic pattern <0.01); the hazard ratio was 1.01 (95% confidence interval, 0.81–1.26) for TSH of 4.5 to 6.9 mIU/L, 1.65 (95% confidence interval, 0.84–3.23) for TSH of 7.0 to 9.9 mIU/L, 1.86 (95% confidence interval, 1.27–2.72) for TSH of 10.0 to 19.9 mIU/L ( P for trend <0.01) and 1.31 (95% confidence interval, 0.88–1.95) for TSH of 0.10 to 0.44 mIU/L and 1.94 (95% confidence interval, 1.01–3.72) for TSH <0.10 mIU/L ( P for trend=0.047). Risks remained similar after adjustment for cardiovascular risk factors. Conclusion—: Risks of heart failure events were increased with both higher and lower TSH levels, particularly for TSH ≥10 and <0.10 mIU/L.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of HF events did not differ after further adjustments for potential confounding risk factors and after the exclusion of patients with preexisting HF or AF [75] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the 648 participants with SHyper, the HR for HF events was significantly increased during a median follow-up of 10.4 years in ageand sex-adjusted analyses, although a limited number of participants were <50 years.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from all the available prospective cohort studies demonstrate that SHyper is associated with an increased risk of total mortality, CHD mortality and incident AF.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, these meta-analyses performed sensitivity analyses excluding participants with missing values of FT 4 and total FT 3 , and used the I 2 statistic to assess heterogeneity across studies.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three recent meta-analyses provide evidence, based also on IPD data, for treating SHyper with undetectable TSH because of an excess risk of total mortality, CHD mortality, HF, incident AF and fractures among adults with grade 2 SHyper [71,75,108,109] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these meta-analyses do not show evidence that treatment is effective in improving the risks associated with untreated SHyper, they demonstrate that SHyper is a potentially life-threatening condition.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The risk of HF was much higher in participants with grade 2 SHyper (HR = 1.94; 95% CI: 1.01-3.72)than in those with grade 1 SHyper (HR = 1.31; 95% CI: 0.88-1.95;p for trend across lower TSH categories 0.047).”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“The task force recognized that two recent meta-analyses have provided relevant information on the cardiovascular outcome of SHyper because they included IPD from all the available prospective studies [71,75] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“The risks of CHD mortality and AF are greater among adults with grade 2 SHyper [71,75] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“They assessed baseline cardiovascular risk factors, pre-existing cardiovascular disease (CVD) and thyroid-altering medication use, and stratified the analysis by age, sex, race and TSH categories [71,75] .”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“Although these meta-analyses do not show evidence that treatment is effective in improving the risks associated with untreated SHyper, they demonstrate that SHyper is a potentially life-threatening condition.”
From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [75]
In the citing paper
“Recent individual patient meta-analysis by the Thyroid Studies Collaboration8,9,10,11 did not find higher risk of CVD and all-cause mortality among adults with subclinical hypothyroidism compared with those with euthyroidism”
From Association of subclinical hypothyroidism and cardiovascular disease with mortality (2020) · cites this paper as [9]
In the citing paper
“The most recent data indicate that SH subjects appear to be at particular risk for the development of heart failure (381,388,392), especially older subjects (381,392) and those with lower TSH levels (392).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [392]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,739
Burden of Systolic and Diastolic Ventricular Dysfunction in the Community
Redfield, M. M., Jacobsen, S. J., Burnett, J. C. J., Mahoney, D. W., Bailey, K. R., & Rodeheffer, R. J. (2003) · JAMA · doi:10.1001/jama.289.2.194 · Cited by 2,989
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,616
Lifetime Risk for Developing Congestive Heart Failure
Lloyd‐Jones, D. M., Larson, M. G., Leip, E. P., Beiser, A., D’Agostino, R. B., Kannel, W. B., Murabito, J. M., Vasan, R. S., Benjamin, E. J., & Levy, D. A. (2002) · Circulation · doi:10.1161/01.cir.0000039105.49749.6f · Cited by 1,615
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
Jessup, M. L., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Rahko, P. S., Silver, M. A., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192064 · Cited by 1,420
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jcem.87.2.8182 · DOI · Paper page
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K. G., & Pearce, S. H. S. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 1,018
Metadata
- Authors
- Gencer, B., Collet, T.-H., Virgini, V., Bauer, D. C., Gussekloo, J., Cappola, A. R., Nanchen, D., den Elzen, W. P. J., Balmer, P., Luben, R. N., Iacoviello, M., Triggiani, V., Cornuz, J., Newman, A. B., Khaw, K.-T., Jukema, J. W., Westendorp, R. G. J., Vittinghoff, E., Aujesky, D., & Rodondi, N.
- Affiliations
- From the Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland (B.G., T.-H.C., D.N., P.B., J.C.); Department of General Internal Medicine, Bern University Hospital, Bern, Switzerland (V.V., D.A., N.R.); Departments of Epidemiology and Biostatistics (D.C.B., E.V.) and Medicine (D.C.B.), University of California San Francisco; Departments of Public Health and Primary Care (J.G., W.P.J.d.E.), Cardiology (J.W.J.), and Gerontology and Geriatrics (R.G.J.W.),...
- University of Pittsburgh (US)
- ORCID
- Venue
- Circulation
- Published
- 2012-08-28
- Volume
- 126
- Issue
- 9
- Pages
- 1040-1049
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC3884576
- OpenAlex
- W2000333200
- Cited by
- 517
- References
- 41
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 36 · 2023: 61 · 2022: 34 · 2021: 48 · 2020: 44 · 2019: 39 · 2018: 37 · 2017: 30 · 2016: 26 · 2015: 39 · 2014: 31 · 2013: 32 · 2012: 7
- FWCI
- 27.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- BORIS (University Library Bern) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- National Science Foundation
- American Heart Association
- Bristol-Myers Squibb
- University of Pittsburgh (P30-AG024827)
- Cancer Research UK
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SPUM 33CM30-124 112, 15103, 138267, 20098, 124112, 320030)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (050.060.810, 05040202)
- National Institutes of Health (N01-AG-6-2103, n01hc085082-026, n01hc085081-021, n01ag062101-007, n01hc045133-001, n01hc085079-024, n01hc015103-009, n01hc085084-005, n01ag062103-006, n01hc085085-011, n01hc085083-027, n01hc085080-026, N01‐AG‐6‐2106, n01ag062106-007, n01hc085086-022, N01-AG-6-2101, n01hc075150-004, n01hc035129-010, n01hc055222-001, N01HC85086, AG-027058, AG 20098, N01HC85079, HL-075366, AG-023629, N01-HC-75150, N01HC-35129, N01HC-15103, N01-HC-45133, HL080295)
- Medical Research Council
- National Institute on Aging (N01‐AG‐6–2101, R01AG028050, R56AG023629, R01AG032317, R01AG020098, R01-AG-15928, R01 AG20098, AG023629, AG027058, N01AG62106, R01AG023629, R01AG015928, N01-AG-62103, R01AG027058, AG-032317, P30AG024827)
- National Heart, Lung, and Blood Institute (N01-HC-85081, N01HC85085, N01 HC085086, AG-023629, N01HC-85083, AG-027058, R01-NR012459, N01HC15103, N01 HC085079, N01HC85082, N01HC‐75150, N01 HC85086, AG-20098, N01 HC035129, HL-075366, N01HC85080, N01AG62101, N01 HC015103, N01HC80007, N01 HC55222, R01HL075366, N01‐HC‐45133, N01AG62106, U01HL080295, N01 HC055222, R01 HL, N01AG62103, AG-15928, HL080295, N01 HC075150, N01 HC045133, N01-HC85079, N01-HC85084, N01HC35129)
- National Institute of Nursing Research (N01-AG-6–2101, N01-AG-6-2103, N01-AG-6–2106, NR012459, R01NR012459)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24AR051895)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- subclinical thyroid dysfunction, heart failure, thyroid-stimulating hormone, subclinical hypothyroidism, subclinical hyperthyroidism, TSH levels, heart failure risk, euthyroidism, free thyroxine, cardiovascular risk factors, individual patient data meta-analysis, prospective cohort, thyroid function tests, heart failure exacerbation, heart failure hospitalization, heart failure mortality, heart failure readmission
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Heart Failure, Humans, Hypothyroidism, Male, Middle Aged, Prospective Studies, Risk, Risk Factors, Sensitivity and Specificity, Thyrotropin, Thyroxine, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
